MY187552A - Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions - Google Patents

Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Info

Publication number
MY187552A
MY187552A MYPI2017001928A MYPI2017001928A MY187552A MY 187552 A MY187552 A MY 187552A MY PI2017001928 A MYPI2017001928 A MY PI2017001928A MY PI2017001928 A MYPI2017001928 A MY PI2017001928A MY 187552 A MY187552 A MY 187552A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical compositions
inflammatory conditions
treating ocular
ocular inflammatory
integrin alpha4
Prior art date
Application number
MYPI2017001928A
Other languages
English (en)
Inventor
Achim Hans-Peter Krauss
Original Assignee
Axerovision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axerovision Inc filed Critical Axerovision Inc
Publication of MY187552A publication Critical patent/MY187552A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MYPI2017001928A 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions MY187552A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Publications (1)

Publication Number Publication Date
MY187552A true MY187552A (en) 2021-09-29

Family

ID=56373100

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017001928A MY187552A (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Country Status (21)

Country Link
US (3) US10413535B2 (cg-RX-API-DMAC7.html)
EP (1) EP3319639B1 (cg-RX-API-DMAC7.html)
JP (2) JP6752276B2 (cg-RX-API-DMAC7.html)
KR (2) KR102440162B1 (cg-RX-API-DMAC7.html)
CN (1) CN107921136A (cg-RX-API-DMAC7.html)
AU (1) AU2016290197B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018000112A2 (cg-RX-API-DMAC7.html)
CA (1) CA2989522C (cg-RX-API-DMAC7.html)
CL (1) CL2018000057A1 (cg-RX-API-DMAC7.html)
ES (1) ES2835274T3 (cg-RX-API-DMAC7.html)
HK (1) HK1247120A1 (cg-RX-API-DMAC7.html)
IL (2) IL256770B (cg-RX-API-DMAC7.html)
MA (2) MA42016A1 (cg-RX-API-DMAC7.html)
MX (1) MX385229B (cg-RX-API-DMAC7.html)
MY (1) MY187552A (cg-RX-API-DMAC7.html)
PL (1) PL3319639T3 (cg-RX-API-DMAC7.html)
RU (1) RU2018103940A (cg-RX-API-DMAC7.html)
TN (1) TN2017000538A1 (cg-RX-API-DMAC7.html)
UA (1) UA123728C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017006272A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708601B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165218A1 (en) 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
KR20220054598A (ko) * 2019-07-26 2022-05-03 알레그로 파마슈티칼스, 엘엘씨 비삼출성 황반변성 및 기타 안질환 치료용 펩티드
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4232458A4 (en) * 2020-10-21 2024-10-02 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
SI1881823T1 (sl) * 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
US8067433B2 (en) * 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
MA42016A1 (fr) 2018-03-30
KR102440162B1 (ko) 2022-09-02
KR20180041122A (ko) 2018-04-23
US20200405703A1 (en) 2020-12-31
US20200000786A1 (en) 2020-01-02
MA44935A1 (fr) 2019-08-30
PL3319639T3 (pl) 2021-03-08
IL256770A (en) 2018-03-29
HK1247120A1 (zh) 2018-09-21
AU2016290197A1 (en) 2018-01-04
MX385229B (es) 2025-03-14
ZA201708601B (en) 2019-05-29
JP2020121985A (ja) 2020-08-13
US10751334B2 (en) 2020-08-25
UA123728C2 (uk) 2021-05-26
MX2017017163A (es) 2018-08-09
US20180200240A1 (en) 2018-07-19
CA2989522A1 (en) 2017-01-12
CA2989522C (en) 2022-10-18
KR20220062688A (ko) 2022-05-17
IL256770B (en) 2021-02-28
TN2017000538A1 (en) 2019-04-12
EP3319639A1 (en) 2018-05-16
JP6752276B2 (ja) 2020-09-09
RU2018103940A (ru) 2019-08-08
CN107921136A (zh) 2018-04-17
IL280827A (en) 2021-04-29
BR112018000112A2 (pt) 2018-09-04
ES2835274T3 (es) 2021-06-22
CL2018000057A1 (es) 2018-06-22
AU2016290197B2 (en) 2021-07-22
WO2017006272A1 (en) 2017-01-12
RU2018103940A3 (cg-RX-API-DMAC7.html) 2019-09-03
JP2018521126A (ja) 2018-08-02
EP3319639B1 (en) 2020-11-18
US10413535B2 (en) 2019-09-17

Similar Documents

Publication Publication Date Title
TN2017000538A1 (en) Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
SA518391624B1 (ar) Ror- منظمات جاما
PH12018501920B1 (en) Bromodomain inhibitors
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
EA201991123A1 (ru) ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
PH12018500284B1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
MD20160012A2 (ro) Formulare de inhibitori SYK
PH12019502850B1 (en) AMIDE DERIVATIVES AS Nav1.7 AND Nav1.8 BLOCKERS
EA201791009A1 (ru) Композиции, содержащие циклоспорин
MX373162B (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda).
MX2019004375A (es) Inhibidores de bromodominios.
EA201691252A1 (ru) Соединения индазола в качестве агонистов 5-ht-рецептора
MX2019004187A (es) Inhibidores de bromodominios.
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль
EA202090432A1 (ru) Новые соединения, активирующие путь nrf2
EP4017500A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANTERIOR BLEPHARITIS AND POSTERIOR BLEPHARITIS
EA033153B1 (ru) Фармацевтическая композиция для лечения воспалительных изменений прямой кишки
MX386462B (es) Composiciones farmaceuticas de antagonista del 5-ht6.
TH1801000059A (th) องค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วยสารต้านอินทีกรินอัลฟา 4 สำหรับใช้ในการรักษาสภาวะตาอักเสบ
UA115290U (xx) Композиція у формі спрею для орального застосування, що містить холіну альфосцерат